Product image of Pantoxobe (Pantoprazole Sodium Sesquihydrate) supplied by GNH India

Pantoxobe

Active Ingredient:
Pantoprazole Sodium Sesquihydrate
Origin:
EU

Pantoxobe (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoxobe, is a proton pump inhibitor presented as an injectable solution for intravenous use. It reduces gastric acid secretion and is used to treat conditions such as erosive oesophagitis, gastric ulcer, and Zollinger‑Ellison syndrome in hospital settings.

GNH India supplies Pantoxobe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Axone, Lda.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Pantoxobe is indicated for several gastrointestinal disorders that involve excess acid production:

  • Erosive oesophagitis: promotes healing of the esophageal lining by reducing acid exposure.
  • Gastric ulcer: supports ulcer resolution through sustained acid suppression.
  • Duodenal ulcer: aids in ulcer healing by maintaining a low‑acid environment.
  • NSAID‑induced ulcer disease: mitigates ulcer risk associated with non‑steroidal anti‑inflammatory drugs.
  • Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid in this rare endocrine disorder.
  • Stress ulcer prophylaxis: prevents stress‑related gastric mucosal damage in critically‑ill patients.

How It Works

  • Pantoprazole irreversibly binds to the H+/K+ ATPase enzyme (gastric proton pump) on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly lowers gastric acidity, allowing mucosal healing and reducing acid‑related injury.

Side Effects

Adverse reactions to Pantoxobe may vary in frequency and severity.

Common Side Effects

  • Headache: mild to moderate pain often resolving without intervention.
  • Diarrhea: loose stools that are usually transient.
  • Nausea: feeling of sickness without vomiting.
  • Abdominal pain: discomfort in the stomach region.
  • Injection site reactions: redness, swelling, or mild pain at the IV site.

Serious or Rare Side Effects

  • Severe hypersensitivity: rash, itching, swelling, or anaphylaxis.
  • Clostridioides difficile infection: persistent diarrhea with possible colitis.
  • Electrolyte disturbances: low magnesium or potassium levels.
  • Acute interstitial nephritis: kidney inflammation presenting with fever and rash.
  • Liver enzyme elevation: increased ALT/AST indicating hepatic stress.

Precautions & Warnings

When using Pantoxobe, clinicians should consider several safety measures:

  • Renal impairment: adjust dosing or monitor renal function in patients with reduced kidney function.
  • Hepatic impairment: use with caution in moderate to severe liver disease.
  • Elderly patients: monitor for increased sensitivity to side effects.
  • Concomitant medications: review for potential drug‑drug interactions before initiating therapy.
  • Pregnancy and lactation: evaluate risk‑benefit ratio as safety data are limited.

Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Pantoxobe can interact with several drug classes, requiring attention to dosing and monitoring.

Major Interactions (Avoid)

  • Ketoconazole: reduced absorption of the antifungal due to increased gastric pH.
  • Atazanavir: decreased plasma levels of the antiretroviral, compromising efficacy.
  • Clopidogrel: diminished activation of the antiplatelet, potentially lowering its effect.

Moderate Interactions (Monitor Closely)

  • Warfarin: possible alteration of INR values, requiring more frequent coagulation monitoring.
  • Digoxin: increased serum concentrations may occur, necessitating level checks.
  • Methotrexate: reduced renal clearance can raise toxicity risk.

Frequently Asked Questions

Pantoxobe is an intravenous formulation of pantoprazole used to manage acid‑related gastrointestinal conditions such as erosive oesophagitis, gastric and duodenal ulcers, NSAID‑induced ulcer disease, Zollinger‑Ellison syndrome, and for stress‑ulcer prophylaxis in critically ill patients.

Pantoprazole irreversibly inhibits the H+/K+ ATPase enzyme, also known as the gastric proton pump, located on the secretory surface of parietal cells. This blockade stops the final step of acid production, leading to a sustained decrease in gastric acidity.

The appropriate dose of Pantoxobe is determined by the prescribing clinician based on the patient’s condition, severity, and renal or hepatic function. Dosing regimens are individualized and should follow the prescriber’s order.

Safety data for pantoprazole in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies when the safety of the fetus or infant cannot be assured.

To request Pantoxobe, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Pantoxobe (pantoprazole) offers similar acid‑suppression efficacy to other PPIs such as omeprazole or esomeprazole, but its intravenous form allows rapid onset and use in patients who cannot take oral medication. It has a favorable interaction profile with fewer CYP‑mediated drug‑drug interactions compared with some oral PPIs.

Pantoxobe should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vials in the original packaging until use to maintain stability.

Pantoxobe is given by intravenous infusion, typically diluted in a compatible IV fluid and administered over several minutes as directed by the prescribing clinician. Administration should follow aseptic technique and institutional infusion protocols.

Serious risks include severe hypersensitivity reactions (anaphylaxis), Clostridioides difficile‑associated diarrhea, electrolyte disturbances such as hypomagnesemia, acute interstitial nephritis, and liver enzyme elevations. Prompt recognition and management of these events are essential.

Pantoxobe is contraindicated in patients with known hypersensitivity to pantoprazole or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, uncontrolled infections, or those taking medications that have major interactions, such as clopidogrel.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.